The Russian Direct Investment Fund (RDIF) and Panacea Biotec launch production of the ‘Sputnik V’ vaccine in India
Both companies have agreed to produce 100 million doses per year
The first batch will be produced at Panacea Biotec’s facilities in Baddi, Himachal Pradesh
They will be shipped to Russia’s Gamaleya Center for quality control
Full-scale production is expected to start this summer
The targeted production of the dual vector Sputnik V vaccine for the first 12 months is 50 Mn doses
